“Not just a statistic”: the history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s–1970s

Marks, Lara

doi:10.1016/s0277-9536(99)00156-2

Cited by 12 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More broadly, the user perspective on the drospirenone debate evidences ongoing tensions between lay and expert approaches to risk. Historically, professionals have emphasized risk data accuracy and validity, whereas patients have argued that personal experiences are crucial to understanding risks (Junod & Marks, 2002; Marks, 1999). Interviewees’ views show that dissatisfaction with professional approaches remains, as patients feel their experiences are disregarded in favor of epidemiological data.…”

Section: Discussionmentioning

confidence: 99%

“…Patients spoke about not having adequate risk information prior to taking Yaz and Yasmin. Interestingly, drug package inserts with risk information were historically introduced as a result of initial pill controversies and patient advocacy (Marks, 1999(Marks, , 2001. However, many decades later, the women interviewed argue that they did not find the presentation of current information adequate or useful.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

“One Blood Clot Is One Too Many”: Affected Vocal Users’ Negative Perspectives on Controversial Oral Contraceptives

Geampana

2019

Qual Health Res

View full text Add to dashboard Cite

In this article, I analyze women’s negative experiences with the fourth generation of contraceptive pills: controversial drugs Yaz and Yasmin. Drawing on in-depth interviews with 24 contraceptive users residing in Canada, I highlight how women who have experienced deleterious side effects understand the risks of hormonal contraception and advocate for changes in health risk communication and prescription drug regulation. Findings show that interviewees did not feel they received adequate risk information prior to starting their new drug regimen nor did they think that pregnancy risks should be used as a comparison point for placing hormonal contraceptive risk into perspective. Patient views were generally underlined by a critique of professional risk/benefit assessment techniques and procedures. To illustrate how the modern complexities of health risk assessment extend to the realm of hormonal contraceptives, I here provide a detailed examination of women’s negative experiences while on the pill.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“One Blood Clot Is One Too Many”: Affected Vocal Users’ Negative Perspectives on Controversial Oral Contraceptives

Geampana

2019

Qual Health Res

View full text Add to dashboard Cite

show abstract

“…Previously, he had battled polio as a medical student at Cambridge before acting as Medical Adviser to Imperial Chemical Industries, the company his father had cofounded in 1926. He was later promoted to Principal Medical Officer and is today remembered as the ‘father of the mini-pill’ for his role in reducing the oestrogenic content of oral contraception ( Inman, 1999 , Inman, 2006 , Marks, 1999 , Marks, 2002 ). Between 1967 and 1978, he was the government advisor chiefly responsible for deciding what action, if any, to take on HPTs.…”

Section: The Early-warning Systemmentioning

confidence: 99%

A historical argument for regulatory failure in the case of Primodos and other hormone pregnancy tests

Olszynko-Gryn¹,

Bjørvik²,

Weßel³

et al. 2018

Reproductive Biomedicine & Society Online

View full text Add to dashboard Cite

The drug Primodos and other hormone pregnancy tests (HPTs) remained on the British market for about a decade after they were first implicated, in 1967, as a possible cause of birth defects. In November 2017, an expert working group (EWG) set up by the Medicines and Healthcare Products Regulatory Agency (MHRA) concluded against such an association. However, it was explicitly ‘not within the remit of the EWG to make formal conclusions or recommendations on the historical system or regulatory failures’, a situation that has left many stakeholders dissatisfied. Placing the question of a teratogenicity to one side, this article takes a more contextual and comparative approach than was possible under the auspices of MHRA. It asks why an unnecessary and possibly even harmful drug was allowed to remain on the British market when a reliable and perfectly safe alternative existed: urine tests for pregnancy. Based on archival research in several countries, this article builds a historical argument for regulatory failure in the case of HPTs. It concludes that the independent review which campaigners are calling for would have the potential to not only bring them a form of closure, but would also shed light on pressing issues of more general significance regarding risk, regulation and communication between policy makers, medical experts and patients.

show abstract

“…Janet added that these pamphlets also reduced women 'to numbers' and 'we are people, not numerical figures'. Similarly, in a study on UK and US policies on thrombotic disease and OCs (Marks, 1999(Marks, : 1139, a significant finding was that many consumers objected to being constructed by the medical profession and government as 'just statistics'.…”

Section: Using Bodies As Tools To Make Disembodied Knowledge Embodiedmentioning

confidence: 99%

Bricolage and Bodies of Knowledge: Exploring Consumer Responses to Controversy about the Third Generation Oral Contraceptive Pill

Hester

2005

Body & Society

View full text Add to dashboard Cite

This article explores a small selection of contraceptive consumers' accounts about the recent third generation oral contraceptive (3GOC) controversy in Aotearoa New Zealand 1 and their responses to it. 2 Much of the literature which analyses health consumers' experiences of and responses to medical encounters and debates either adopts a quantitative approach and is located within a medical and 1995b) or argues that consumers privilege experiential information over other types of knowledge, such as medical or epidemiological information, often rejecting the latter (Arksey, 1994;Stacey, 1994;Tuckett et al., 1985;Williams and Popay, 1994). My study utilizes a different orientation which attempts to illustrate the ways in which some consumers use experiential information that is derived from a range of sources (including their own and other women's Body & Society

show abstract

“Not just a statistic”: the history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s–1970s

Cited by 12 publications

References 38 publications

“One Blood Clot Is One Too Many”: Affected Vocal Users’ Negative Perspectives on Controversial Oral Contraceptives

“One Blood Clot Is One Too Many”: Affected Vocal Users’ Negative Perspectives on Controversial Oral Contraceptives

A historical argument for regulatory failure in the case of Primodos and other hormone pregnancy tests

Bricolage and Bodies of Knowledge: Exploring Consumer Responses to Controversy about the Third Generation Oral Contraceptive Pill

Contact Info

Product

Resources

About